Antiangiogenic therapy in myelodysplastic syndromes: Is there a role?

Current Hematologic Malignancy Reports

Volumn 3, Issue 1, 2008, Pages 10-18

  Oh, Stephen T ^b   Gotlib, Jason ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; A 170634; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; AXITINIB; AZACITIDINE; BEVACIZUMAB; LENALIDOMIDE; LONAFARNIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SEMAXANIB; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL DENSITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CARCINOMA; CONSTIPATION; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; LEUKEMIA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; POLYCYTHEMIA; PROMYELOCYTIC LEUKEMIA; REVIEW; SEDATION; SIDE EFFECT; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ARSENICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FARNESYLTRANSTRANSFERASE; HEMATOLOGIC NEOPLASMS; HUMANS; MYELODYSPLASTIC SYNDROMES; NEOVASCULARIZATION, PATHOLOGIC; OXIDES; PROTEIN-TYROSINE KINASES; THALIDOMIDE;

EID: 41849100365     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0003-0     Document Type: Review

References (67)

1. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
2. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
4. Midgley R, Kerr D: Bevacizumab - current status and future directions. Ann Oncol 2005, 16:999-1004.
5. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
6. Faivre S, Djelloul S, Raymond E: New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006, 33:407-420.
7. Rock EP, Goodman V, Jiang JX, et al.: Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007, 12:107-113.
8. Brunner G, Nguyen H, Gabrilove J, et al.: Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 1993, 81:631-638.
9. Leung DW, Cachianes G, Kuang WJ, et al.: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
10. Podar K, Anderson KC: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383-1395. Concise review of biology of VEGF, its role in hematologic malignancies, and methods for targeting VEGF for therapeutic purposes.
11. List AF: Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 2001, 6(Suppl 5):24-31.
12. Ziegler BL, Valtieri M, Porada GA, et al.: KDR receptor: a key marker defining hematopoietic stem cells. Science 1999, 285:1553- 1558.
13. Aguayo A, Estey E, Kantarjian H, et al.: Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999, 94:3717-3721.
14. Giles FJ: The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist 2001, 6(Suppl 5):32-39.
15. Hussong JW, Rodgers GM, Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
16. Aguayo A, Kantarjian H, Manshouri T, et al.: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-2245.
17. Lundberg LG, Lerner R, Sundelin P, et al.: Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000, 157:15-19.
18. Vacca A, Ribatti D: Bone marrow angiogenesis in multiple myeloma. Leukemia 2006, 20:193-199.
19. Rajkumar SV, Leong T, Roche PC, et al.: Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000, 6:3111-3116.
20. Kumar S, Gertz MA, Dispenzieri A, et al.: Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004, 34:235-239.
21. Pruneri G, Bertolini F, Soligo D, et al.: Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999, 81:1398-1401.
22. Alexandrakis MG, Passam FH, Pappa CA, et al.: Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. Int J Immunopathol Pharmacol 2005, 18:287-295.
23. Wimazal F, Krauth MT, Vales A, et al.: Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma 2006, 47:451-460.
24. Alexandrakis MG, Passam FH, Kyriakou DS, et al.: Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. J Mol Histol 2004, 35:857-863.
25. Lundberg LG, Hellstrom-Lindberg E, Kanter-Lewensohn L, et al.: Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res 2006, 30:247-253. Well-studied cohort of 56 patients followed for at least 5 years, showing no correlation between MVD and several clinicopathologic variables, including IPSS score.
26. Keith T, Araki Y, Ohyagi M, et al.: Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 2007, 137:206-215.
27. Aguayo A, Kantarjian HM, Estey EH, et al.: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002, 95:1923-1930.
28. Bellamy WT, Richter L, Sirjani D, et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427-1434. Most convincing data showing possible functional relevance of VEGF in hematologic malignancies, demonstrating that VEGF inhibition inhibited leukemia colony formation from samples from patients with MDS, while VEGF promoted colony formation.
29. Alexandrakis MG, Passam FH, Pappa CA, et al.: Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 2005, 29:41-46.
30. Brunner B, Gunsilius E, Schumacher P, et al.: Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 2002, 11:119-125.
31. Lai R, Estey E, Shen Y, et al.: Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 2002, 94:14-17.
32. Hu Q, Dey AL, Yang Y, et al.: Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 2004, 100:1884-1891.
33. Alvi S, Borok RZ, Shaher A, et al.: Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients [abstract]. Blood 2002, 100:375a. Abstract 1454.
34. Shetty V, Alvi S, Zorat F, et al.: Effect of the antiangiogenic thalidomide on the biological characteristics of patients with myelodysplastic syndromes [abstract]. Blood 2002, 100:337b. Abstract 4902.
35. Raza A, Meyer P, Dutt D, et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98:958-965.
36. Moreno-Aspitia A, Colon-Otero G, Hoering A, et al.: Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer 2006, 107:767-772.
37. Strupp C, Germing U, Aivado M, et al.: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002, 16:1-6.
38. Bouscary D, Legros L, Tulliez M, et al.: A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol 2005, 131:609-618.
39. Richardson PG, Schlossman RL, Weller E, et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
40. Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
41. Gupta D, Treon SP, Shima Y, et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
42. Mahadevan D, List AF, Tate W, et al.: The immunomodulatory thalidomide analog CC5013 is a potent receptor tyrosine kinase (RTK) inhibitor that abolishes vascular endothelial growth factor (VEGF) trophic response in malignant myeloid progenitors. Leuk Res 2003, 27:S108-S109.
43. List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557. This article and List et al. [44••] report on phase 1 and 2 clinical trials demonstrating efficacy of lenalidomide in MDS, particularly the 5q- subtype.
44. List A, Dewald G, Bennett J, et al.: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465. This article and List et al. [43••] report on phase 1 and 2 clinical trials demonstrating efficacy of lenalidomide in MDS, particularly the 5q- subtype.
45. Raza A, Reeves JA, Feldman EJ, et al.: Phase II study of lenalidomide in transfusion-dependent, low- and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2007, In press.
46. Buesche G, Dieck S, Giagounidis A, et al.: Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease [abstract]. Blood 2005, 106:113a.
47. List A, Beran M, DiPersio J, et al.: Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003, 17:1499-1507.
48. Miller WH Jr, Schipper HM, Lee JS, et al.: Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893-3903.
49. Lew YS, Brown SL, Griffin RJ, et al.: Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999, 59:6033-6037.
50. Roboz GJ, Dias S, Lam G, et al.: Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000, 96:1525-1530.
51. Schiller GJ, Slack J, Hainsworth JD, et al.: Phase II multicenter study of arsenic trioxide in patients with myelodysplastic Syndromes. J Clin Oncol 2006, 24:2456-2464. This article and Vey et al. [52•] report results of phase 2 trials evaluating arsenic trioxide in MDS, showing HI in about 20% of patients.
52. Vey N, Bosly A, Guerci A, et al.: Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006, 24:2465-2471. This article and Schiller et al. [51•] report results of phase 2 trials evaluating arsenic trioxide in MDS, showing HI in about 20% of patients.
53. Giles FJ, Stopeck AT, Silverman LR, et al.: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003, 102:795-801.
54. Giles FJ, Bellamy WT, Estrov Z, et al.: The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res 2006, 30:801-811.
55. Gupta P, Sanford BL, Yu D, et al.: A phase II study of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105 [abstract]. Blood 2006, 108:753a.
56. Parker J, Mufti GJ: Ras and myelodysplasia: lessons from the last decade. Semin Hematol 1996, 33:206-224.
57. Casey PJ, Solski PA, Der CJ, et al.: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989, 86:8323-8327.
58. Fenaux P, Raza A, Mufti GJ, et al.: A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007, 109:4158-4163. Phase 2 trial of the FTI tipifarnib in MDS, showing overall response of 32%, including 15% complete remissions and 17% HIs.
59. Delmas C, End D, Rochaix P, et al.: The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res 2003, 9:6062-6068.
60. Izbicka E, Campos D, Carrizales G, et al.: Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. Anticancer Res 2005, 25:3215-3223.
61. Gu WZ, Tahir SK, Wang YC, et al.: Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur J Cancer 1999, 35:1394-1401.
62. Desrosiers RR, Cusson MH, Turcotte S, et al.: Farnesyl-transferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration. Int J Cancer 2005, 114:702-712.
63. Takada Y, Khuri FR, Aggarwal BB: Protein farnesyl-transferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004, 279:26287-26299.
64. Han JY, Oh SH, Morgillo F, et al.: Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005, 97:1272-1286.
65. Cortes J, Albitar M, Thomas D, et al.: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003, 101:1692-1697.
66. Mesa RA, Camoriano JK, Geyer SM, et al.: A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007, 21:1964-1970.
67. Gotlib J, Jamieson CHM, List A, et al.: Phase II study of bevacizumab (anti-vegf humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): preliminary results [abstract]. Blood 2003, 102:425a. Abstract 1545.